<DOC>
	<DOCNO>NCT02809053</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , parallel-group study evaluate statistical equivalence efficacy , assess safety SAIT101 versus MabThera® asymptomatic patient LTBFL . Patients randomize 1:1 ratio receive study drug week 4 week , follow 52 week first dose .</brief_summary>
	<brief_title>A Randomized , Double-blind , Multi-center , Multi-national Trial Evaluate Efficacy , Safety , Immunogenicity SAIT101 Versus Rituximab First-line Immunotherapy Treatment Patients With Low Tumor Burden Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients histologicallyconfirmed Low Tumor Burden Follicular Lymphoma , without B symptom , Ann Arbor stage II IVA NHL ( CD20+ FL Grades 1 , 2 , 3a ) 2 . Low tumor burden accord GELF criterion define : Normal serum lactate dehydrogenase ( LDH ) β2microglobulin level . No mass ≥7 cm . Less 3 mass &gt; 3 cm . No systemic B symptom ( fever &gt; 38°C 3 consecutive day ; recurrent , drench night sweat ; unintentional weight loss exceed 10 % body weight last 6 month . No splenomegaly ≥16 cm CT scan . No risk vital organ compression . No pleural peritoneal serous effusion . No leukemic phase &gt; 5,000/µL circulate tumor cell . No cytopenia ( define platelet &lt; 100,000/mm3 , hemoglobin &lt; 10 g/dL , absolute neutrophil count &lt; 1,500/mm3 ) . 3 . Patients previously treat FL , include previous treatment FL clinical trial except localized radiation therapy previous limited stage disease . 1 . Previous treatment chemotherapy and/or rituximab monoclonal antibody . 2 . Prior radiotherapy complete &lt; 28 day study enrollment . 3 . Anticipated need concomitant administration experimental drug , concomitant chemotherapy , anticancer hormonal therapy , radiotherapy , immunotherapy study participation . 4 . Concomitant disease require continuous therapy corticosteroid dose equivalent prednisolone &gt; 20 mg/day . 5 . Transformation highgrade lymphoma secondary previously untreated lowgrade lymphoma . 6 . Prior concomitant malignancy within 5 year prior screen , exception nonmelanoma skin cancer , adequately treat carcinoma situ cervix , adequately treat breast cancer situ , localized prostate cancer stage T1c , provide patient underwent curative treatment remain relapse free . 7 . Patients body surface area &gt; 3.0 m2 . 8 . Major surgery ( exclude lymph node biopsy ) within 28 day prior randomization . 9 . Primary secondary immunodeficiency ( history , currently active ) , include know history human immunodeficiency virus ( HIV ) infection positive test screening . 10 . Acute , severe infection ( e.g. , sepsis opportunistic infection ) , active , chronic persistent infection might worsen immunosuppressive treatment ( e.g. , herpes zoster ) . 11 . Positive serological test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) hepatitis C serology . Patients negative HBsAg positive HBcAb must hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) level &lt; 20 IU/mL ( 112 copies/mL ) polymerase chain reaction ( PCR ) . These HBV patient must willing undergo PCR HBV DNA test treatment may participate follow consultation hepatitis expert regard monitoring use HBV antiviral therapy , provide agree receive treatment indicate . An HBV retest perform study visit Week 5 onwards , discretion Investigator . Patients positive test HBV vaccine may include ( i.e. , antiHBs+ , antiHBc ) . Patients positive hepatitis C virus ( HCV ) antibody eligible PCR negative HCV ribonucleic acid ( RNA ) . 12 . Confirmed current active tuberculosis ( TB ) . Patients latent TB determine positive QuantiFERONTB test may enrol patient write confirmation health care provider ( e.g. , Pulmonologist Infection Specialist ) adequate prophylaxis within screen period , evidence tuberculosis chest Xray perform within 3 month Day 1 . 13 . Central nervous system ( CNS ) meningeal involvement , cord compression lymphoma ; history CNS lymphoma . A brain scan conduct screen ONLY lesion suspect brain , exclude patient brain localization FL . 14 . History severe allergic reaction anaphylactic reaction biological agent history hypersensitivity component trial drug ( e.g. , hypersensitivity allergy murine product ) . 15 . Patients significant cardiac disease , include limited history congestive heart failure ( New York Heart Association Class III/IV ; see Appendix 7 ) , unstable angina , uncontrolled cardiac arrhythmia . 16 . Uncontrolled severe hypertension , cerebrovascular disease . 17 . Serious underlie medical condition , per Investigator 's discretion , could impair ability patient participate trial ( include limit ongoing active infection , severe immunosuppression , uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease ) . 18 . Any coexist medical psychological condition ( ) preclude participation study compromise ability give inform consent and/or comply study procedure . 19 . Treatment investigational medicinal product ( IMP ) within 4 week prior initiation 1st infusion study drug , treatment drug receive regulatory approval indication within 4 week minimum 5 halflives , whichever long , 1st infusion study drug . 20 . Receipt live/attenuated vaccine within 6 week prior screen visit . 21 . Females pregnant , breastfeeding , plan pregnancy treatment period within 12 month last infusion study drug . 22 . Patients investigational site staff member directly involved conduct trial , family member , site staff member otherwise supervised investigator , patient Archigen employee directly involve conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>low tumor burden follicular lymphoma ( LTBFL )</keyword>
</DOC>